FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915133037> ?p ?o ?g. }

• W2915133037 endingPage "33" @default.
• W2915133037 startingPage "27" @default.
• W2915133037 abstract "Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Combining consolidative chemotherapy with TKIs may increase rates of infectious complications, organ toxicity, hospitalization, and non-relapse mortality. Blinatumomab has demonstrated single-agent activity in patients with relapsed B-ALL or persistent MRD, including Ph + B-ALL. We have used blinatumomab concomitantly with commercially available TKIs as consolidative therapy to spare toxicities of conventional chemotherapy. We evaluated 11 adults with previously treated Ph + B-ALL who received blinatumomab concurrent with TKI (ponatinib, n = 5; dasatinib, n = 4; nilotinib, n = 1; imatinib, n = 1) to eradicate MRD or sustain MRD-negativity. Eight of 9 patients with MRD achieved BCR-ABL1 negativity (complete molecular response, CMR) after a median of one cycle; 2/2 patients without measurable disease durably maintained CMR. Cytokine release syndrome (all grade 1-2) was observed in 3/11 patients; one patient experienced transient grade 1 neurologic toxicity. Transient grade 2 transaminitis was observed in 6/11 patients, including 4/5 recipients of blinatumomab + ponatinib. This small series suggests blinatumomab + TKI is a safe and effective consolidation strategy for patients with Ph + ALL to achieve or maintain CMR." @default.
• W2915133037 created "2019-03-02" @default.
• W2915133037 creator A5001124933 @default.
• W2915133037 creator A5007818158 @default.
• W2915133037 creator A5040703931 @default.
• W2915133037 creator A5064294460 @default.
• W2915133037 creator A5071975128 @default.
• W2915133037 date "2019-04-01" @default.
• W2915133037 modified "2023-10-03" @default.
• W2915133037 title "Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia" @default.
• W2915133037 cites W1685744202 @default.
• W2915133037 cites W1967348190 @default.
• W2915133037 cites W1991644988 @default.
• W2915133037 cites W1993808217 @default.
• W2915133037 cites W1996697756 @default.
• W2915133037 cites W2001388714 @default.
• W2915133037 cites W2013779251 @default.
• W2915133037 cites W2033862877 @default.
• W2915133037 cites W2039201527 @default.
• W2915133037 cites W2047597898 @default.
• W2915133037 cites W2051536771 @default.
• W2915133037 cites W2054251966 @default.
• W2915133037 cites W2063898537 @default.
• W2915133037 cites W2065851457 @default.
• W2915133037 cites W2068216890 @default.
• W2915133037 cites W2073035156 @default.
• W2915133037 cites W2082708772 @default.
• W2915133037 cites W2089224414 @default.
• W2915133037 cites W2107925822 @default.
• W2915133037 cites W2112505356 @default.
• W2915133037 cites W2124174337 @default.
• W2915133037 cites W2132541027 @default.
• W2915133037 cites W2141106022 @default.
• W2915133037 cites W2145822190 @default.
• W2915133037 cites W2147109509 @default.
• W2915133037 cites W2147545245 @default.
• W2915133037 cites W2158175056 @default.
• W2915133037 cites W2159507916 @default.
• W2915133037 cites W2166295047 @default.
• W2915133037 cites W2296061031 @default.
• W2915133037 cites W2344488712 @default.
• W2915133037 cites W2576962736 @default.
• W2915133037 cites W2582896768 @default.
• W2915133037 cites W2591709377 @default.
• W2915133037 cites W2599899418 @default.
• W2915133037 cites W2745344769 @default.
• W2915133037 cites W2787145330 @default.
• W2915133037 cites W2790692615 @default.
• W2915133037 cites W2794218805 @default.
• W2915133037 cites W2902317207 @default.
• W2915133037 doi "https://doi.org/10.1016/j.leukres.2019.02.009" @default.
• W2915133037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7536787" @default.
• W2915133037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30831480" @default.
• W2915133037 hasPublicationYear "2019" @default.
• W2915133037 type Work @default.
• W2915133037 sameAs 2915133037 @default.
• W2915133037 citedByCount "51" @default.
• W2915133037 countsByYear W29151330372019 @default.
• W2915133037 countsByYear W29151330372020 @default.
• W2915133037 countsByYear W29151330372021 @default.
• W2915133037 countsByYear W29151330372022 @default.
• W2915133037 countsByYear W29151330372023 @default.
• W2915133037 crossrefType "journal-article" @default.
• W2915133037 hasAuthorship W2915133037A5001124933 @default.
• W2915133037 hasAuthorship W2915133037A5007818158 @default.
• W2915133037 hasAuthorship W2915133037A5040703931 @default.
• W2915133037 hasAuthorship W2915133037A5064294460 @default.
• W2915133037 hasAuthorship W2915133037A5071975128 @default.
• W2915133037 hasConcept C104317684 @default.
• W2915133037 hasConcept C121608353 @default.
• W2915133037 hasConcept C126322002 @default.
• W2915133037 hasConcept C138626823 @default.
• W2915133037 hasConcept C143998085 @default.
• W2915133037 hasConcept C185592680 @default.
• W2915133037 hasConcept C2777413986 @default.
• W2915133037 hasConcept C2777583451 @default.
• W2915133037 hasConcept C2778020697 @default.
• W2915133037 hasConcept C2778461978 @default.
• W2915133037 hasConcept C2778729363 @default.
• W2915133037 hasConcept C2778820342 @default.
• W2915133037 hasConcept C2778904597 @default.
• W2915133037 hasConcept C2779536868 @default.
• W2915133037 hasConcept C2779823535 @default.
• W2915133037 hasConcept C2780381907 @default.
• W2915133037 hasConcept C2909962599 @default.
• W2915133037 hasConcept C55493867 @default.
• W2915133037 hasConcept C71924100 @default.
• W2915133037 hasConceptScore W2915133037C104317684 @default.
• W2915133037 hasConceptScore W2915133037C121608353 @default.
• W2915133037 hasConceptScore W2915133037C126322002 @default.
• W2915133037 hasConceptScore W2915133037C138626823 @default.
• W2915133037 hasConceptScore W2915133037C143998085 @default.
• W2915133037 hasConceptScore W2915133037C185592680 @default.
• W2915133037 hasConceptScore W2915133037C2777413986 @default.
• W2915133037 hasConceptScore W2915133037C2777583451 @default.
• W2915133037 hasConceptScore W2915133037C2778020697 @default.
• W2915133037 hasConceptScore W2915133037C2778461978 @default.
• W2915133037 hasConceptScore W2915133037C2778729363 @default.

• next